Individuals with IMIDs had a higher risk of COVID-19 death (HR 1.23) and hospitalisation (HR 1.32) compared to the general population. However, most targeted therapies did not increase the risk of severe COVID-19 outcomes compared to standard treatments.
Positive outcomes include improved understanding of disease progression, identification of early predictors of disease activity, and enhanced prognosis for patients through targeted treatment strategies.
The study aims to demonstrate that CBD transdermal patches can significantly reduce psoriasis severity, as measured by the local psoriasis severity index (LPSI) and itch scores, potentially offering a novel and effective treatment option for patients suffering from psoriasis.
Inhibition of GSDMD in neutrophils mitigates psoriasis-like inflammation in mice, reducing the release of inflammatory cytokines and attenuating skin inflammation.
Healthy controls and IMID patients on biologic treatments demonstrated robust antibody responses over 90%, indicating effective immunogenicity in these groups.
The study found that psoriatic patients had a higher prevalence of gastrointestinal symptoms compared to healthy controls. Additionally, mice receiving healthy microbiota showed better recovery from psoriasiform dermatitis compared to those receiving psoriatic microbiota, indicating a potential therapeutic role of gut microbiota in psoriasis management.
The findings support the therapeutic potential of agents that inhibit Th2 responses, which may improve treatment outcomes for patients with PPP. The study also establishes a causal link between cigarette smoking and the disease, suggesting that smoking cessation could be beneficial.
Patients exhibited robust antibody responses to the vaccines, with neutralizing antibodies comparable to healthy controls, and stable disease activity and biomarkers over the vaccination period.
Treatment with methotrexate and bDMARDs led to changes in the skin microbiota and improvements in the immunophenotype, indicating a positive response in these areas. However, the stool microbiome remained dysbiotic, suggesting a need for further investigation.
The study found that the use of anti-ILAb and TNF-inhibitors was associated with distinct microbial abundances and diversities over time, indicating potential for these microbiota profiles to serve as biomarkers for personalized treatment plans in moderate-to-severe psoriasis patients.